Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
-
Companies To Watch: Aurion Biotech
Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
-
Companies To Watch: Athira Pharma
Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
-
Companies To Watch: Volastra Therapeutics
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
Companies To Watch: OSE Immunotherapeutics
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
Companies To Watch: Antiva Biosciences
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
Companies to Watch: Promontory Therapeutics
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
Companies To Watch: KeifeRx
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
Companies To Watch: Freya Biosciences
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
-
Companies To Watch: Spruce Biosciences
Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.
-
Companies To Watch: Nido Biosciences
See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
-
Companies To Watch: Ventoux Biosciences
Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.
-
Companies To Watch: Kinaset Therapeutics
Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.
-
Companies To Watch: Orca Bio
Orca Bio is creating a new cell therapy aimed at bringing rebirth to stem-cell transplantation.
-
Companies To Watch: Sonoma Biotherapeutics
Sonoma Biotherapeutics is bioengineering T cells to create potential cures for autoimmune and inflammatory conditions.
IN THIS MONTH'S ISSUE
- Gene Editing Versus Gene Therapy: Is There A Difference?
- The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
- Ensuring Diversity And Accessibility In Neurological Research
- A New Year's Resolution Suggestion For The FDA
- Pharma's Customer Engagement Evolution: Is Your Data Governance Keeping Pace?
BEYOND THE PRINTED PAGE
-
2023 Manufacturing And Supply Chain Outlook: Additional Insights12/16/2022
Additional executive responses to our 2023 manufacturing and supply chain outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 212/9/2022
Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 112/2/2022
Biopharma executives offer options, tips and strategies for navigating finance and funding challenges in 2023.